- Home
- PMVP
as 06-20-2025 4:00pm EST
PMV Pharmaceuticals Inc is a precision oncology company. The company is engaged in the research and development of small molecule, tumor-agnostic therapies targeting p53 mutations, which can eliminate cancer cells. Its pipeline rezatapopt PYNNACLE, rezatapopt and azacitidine, rezatapopt (PC14586), and PMV-586-101.
| Founded: | 2013 | Country: | United States |
| Employees: | N/A | City: | PRINCETON |
| Market Cap: | 55.1M | IPO Year: | 2020 |
| Target Price: | $5.00 | AVG Volume (30 days): | 362.7K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 1 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.18 | EPS Growth: | N/A |
| 52 Week Low/High: | $0.81 - $1.82 | Next Earning Date: | 08-07-2025 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Latest PMV Pharmaceuticals Inc. News
PMVP Breaking Stock News: Dive into PMVP Ticker-Specific Updates for Smart Investing
GlobeNewswire
a month ago
PMV Pharmaceuticals to Participate at Upcoming Investor Conferences
Simply Wall St.
a month ago
We're Keeping An Eye On PMV Pharmaceuticals' (NASDAQ:PMVP) Cash Burn Rate
GlobeNewswire
a month ago
PMV Pharmaceuticals Reports First Quarter 2025 Financial Results and Corporate Highlights
Zacks
4 months ago
Here's Why PMV Pharmaceuticals (PMVP) Looks Ripe for Bottom Fishing
GlobeNewswire
4 months ago
PMV Pharmaceuticals Reports Full Year 2024 Financial Results and Corporate Highlights
Simply Wall St.
4 months ago
3 US Penny Stocks To Consider In February 2025
GlobeNewswire
4 months ago
PMV Pharmaceuticals to Participate at Upcoming Investor Conferences
Simply Wall St.
5 months ago
US Penny Stocks To Watch In January 2025
Compare PMVP vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "PMVP PMV Pharmaceuticals Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.